Prucalopride

Drugs

Volumn 69, Issue 17, 2009, Pages 2463-2476

  Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DIGOXIN; ERYTHROMYCIN; KETOCONAZOLE; PAROXETINE; PLACEBO; PROBENECID; PRUCALOPRIDE; WARFARIN;

ABDOMINAL DISTENSION; AREA UNDER THE CURVE; BACKACHE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLATULENCE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; NAUSEA; PATIENT ASSESSMENT; QT PROLONGATION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SINUSITIS; UPPER ABDOMINAL PAIN; VIRUS INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZOFURANS; CATHARTICS; CHILD; CHILD, PRESCHOOL; CONSTIPATION; COST OF ILLNESS; DEFECATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRANSIT; HUMANS; INFANT; LAXATIVES; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PATIENT SATISFACTION; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN; SEROTONIN AGONISTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 72049098520     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204000-000000000-00000     Document Type: Review

References (54)

1. Dennison C, Prasad M, Lloyd A, et al. The health-related quality of life and economic burden of constipation. Pharmacoeco-nomics 2005; 23 (5): 461-476
2. Stewart WF, Liberman JN, Sandler RS, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gas-troenterol 1999 Dec; 94 (12): 3530-3540
3. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004 Apr; 99 (4): 750-759
4. Gallagher PF, O'Mahony D, Quigley EMM. Management of chronic constipation in the elderly. Drugs Aging 2008; 25 (10): 807-821
5. Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001 Nov; 96 (11): 3130-3137
6. Lembo A, Camilleri M. Chronic constipation. New Engl J Med 2003 Oct 2; 349 (14): 1360-1368
7. Spinzi G, Amato A, Imperiali G, et al. Constipation in the elderly: management strategies. Drugs Aging 2009; 26 (6): 469-474
8. Irvine EJ, Ferrazzi S, Pare P, et al. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002 Aug; 97 (8): 1986-1993
9. Johanson JF. Review of the treatment options for chronic constipation. MedGenMed 2007; 9: 25
10. Jones MP, Talley NJ, Nuyts G, et al. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci 2002 Oct; 47 (10): 2222-2230
11. Petticrew M, Rodgers M, Booth A, et al. Effectiveness of laxatives in adults. Qual Health Care 2001; 10: 268-273
12. Tramonte SM, Brand MB, Mulrow CD, et al. The treatment of chronic constipation in adults: a systematic review. J Gen Intern Med 1997; 12: 15-24
13. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009 Mar; 58 (3): 357-365
14. McKeage K, Plosker GL, Siddiqui MA. Lubiprostone. Drugs 2006; 66 (6): 873-879
15. Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009 Jan; 104 (1): 125-132
16. De Maeyer JH, Lefebvre RA, Schuurkes JA, et al. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008 Feb; 20 (2): 99-112
17. Briejer MR, Bosmans JP, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001 Jun 29; 423 (1): 71-83
18. Rabesseda X, Castaner J. Prucalopride. Drugs Future 1999; 24 (7): 729-734
19. Potet F, Bouyssou T, Escande D, et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K+ channel. JPET 2001; 299: 1007-1012
20. Prins NH, Van Haselen JFWR, Lefebvre RA, et al. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol 1999; 127: 1431-1437
21. Prins NH, Shankley NP, Welsh NJ, et al. An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle. Br J Pharmacol 2000 Apr; 129 (8): 1601-1608
22. Cellek S, John AK, Thangiah R, et al. 5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterol Motil 2006 Sep; 18 (9): 853-861
23. Leclere PG, Prins NH, Schuurkes JA, et al. 5-HT4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterol Motil 2005 Jun; 17 (3): 366-375
24. De Schryver AM, Andriesse GI, Samsom M, et al. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002 Mar; 16 (3): 603-612
25. Emmanuel AV, Kamm MA, Roy AJ, et al. Effect of a novel prokinetic drug, RO93877, on gastrointestinal transit in healthy volunteers. Gut 1998; 42: 511-516
26. Bouras EP, Camilleri M, Burton DD, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, pru-calopride, in healthy humans. Gut 1999 May; 44 (5): 682-686
27. Poen AC, Felt-Bersma RJ, Van Dongen PA, et al. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999 Nov; 13 (11): 1493-1497
28. Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002 Apr; 16 (4): 759-767
29. Coremans G, Kerstens R, De Pauw M, et al. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief: results of a double-blind, placebo-controlled clinical trial. Digestion 2003; 67 (1-2): 82-89
30. Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002 Jul; 16 (7): 1347-1356
31. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001 Feb; 120 (2): 354-360
32. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008 May 29; 358 (22): 2344-2354
33. Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerabili-ty of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009 Feb 1; 29 (3): 315-328
34. Nichols TW, Beyens G, Ausma J, et al. A double-blind, placebo-controlled, dose-finding trial to evaluate the efficacy and safety of prucalopride in patients with chronic constipation [abstract no. P0894]. Gut 2008 Oct 21; 57 Suppl. II: A283
35. Van Outryve M, Bosseckert H, Bouchoucha M, et al. Effects of the novel enterokinetic, prucalopride, in patients with chronic constipation: a double-blind, placebo-controlled, multicentre study [abstract no. P1377]. Gut 1999 Nov; 45 Suppl. V: A341
36. Mueller-Lissner SA, Rykx A, Kerstens R, etal. Randomized double-blind placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor®) in elderly patients with chronic constipation [abstract no. 1052]. Gastroenterology 2008 Apr; 134 (4 Suppl. 1): A157
37. Van De Vel De V Ausma J, Vandeplassche L. Pharmacokinetics of prucalorpide (Resolor®) in man [abstract no. P0891]. Gut 2008 Oct 21; 57 Suppl. II*A282
38. Plus poster presented at the 16th United European Gastroenterology Week; 2008 Dec 18-22
39. Vienna Data on file, Movetis NV, 2009 Tack J, Ausma J, Kerstens R, et al. Efficacy and safety of 12-week treatment with prucalopride in patients with severe chronic constipation: combined results of 3 identical, double-blind, placebo-controlled trials [abstract]. XXIst Belgian Week of Gastroenterology; 2009 Feb 12-14; Antwerp
40. Camilleri M, Gryp RS, Kerstens R, et al. Efficacy of 12-week treatment with prucalopride (Resolor®) in patients with chronic constipation: combined results of three identical randomized double-blind, placebo controlled phase III trials [abstract no. T1402]. Gastroenterology 2008 Apr; 134 (4 Suppl. 1): A548
41. Tack J, Dubois D, Kerstens R, et al. PAC-QOL results from 3 identical randomized placebo-controlled trials with prucalopride in patients with severe chronic constipatiion [abstract no. T1259]. Gastroenterology 2009; 136 (4 Suppl. 1): A533
42. Movetis. Efficacy and safety study of prucalopride for the treatment of elderly patients with chronic constipation [Clini-calTrials.gov identifier NCT00487422]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Sep 15]
43. Movetis. Efficacy and safety study of prucalopride for the retreatment of chronic constipation [ClinicalTrials.gov identifier NCT00598338]. US National Institutes of Health, ClinicalTri-als.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Sep 15]
44. Galandiuk S, Rykx A, Ausma J, et al. A two-period, double-blind, placebo-controlled study to evaluate the effects of re-treatment of prucalopride (Resolor) on efficacy and safety in patients with chronic constipation [abstract no. OP398]. Gut 2008 Oct 22; 57 Suppl. II: A86
45. Movetis. Efficacy and safety study of the effect of dose-titration of prucalopride for the treatment of chronic constipation [Clin-icalTrials.gov identifier NCT00577018]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Sep 15]
46. Van Outryve MJ, Beyens G, Kerstens R, et al. Long term follow up study of oral prucalopride (Resolor®) administered to patients with chronic constipation [abstract no. T1400]. Gastroenterology 2008 Apr; 134 (4 Suppl. 1): A547. Plus poster presented at Digestive Disease Week; 2008 May 17-22; San Diego (CA)
47. Camilleri M, Beyens G, Kerstens R, et al. Long-term follow-up of safety and satisfaction with bowel function in response to oral prucalopride in patients with chronic constipation [abstract no. 160]. Gastroenterology 2009; 136 (Suppl. 1): A31
48. Tack JF, Ausma J, Kerstens R, et al. Safety and tolerability of prucalopride (Resolor®) in patients with chronic constipation: pooled data from three pivotal phase III studies [abstract no. T1322]. Gastroenterology 2008 Apr; 134 (4 Suppl. 1): A530. Plus poster presented at Digestive Disease Week; 2008 May 17-22; San Diego (CA)
49. Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009 Sep 9
50. Boyce M, Kerstens R, Beyens G, et al. Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trials [abstract no. T1265]. Gastroenterology 2009; 136 (4 Suppl. 1): A535
51. Boyce M, Mertens A, Mannaert E, et al. Tolerability and cardiac safety of prucalopride (PRU) in healthy volunteers [abstract no. 404]. Am J Gastroenterol 2000 Sep; 95 (9): 2529
52. Boyce MJ, Carey W, Mannaert E, et al. Cardiovascular safety of prucalopride (Resolor®) in healthy subjects: results from a randomized double blind placebo controlled cross over trial [abstract no. T1418]. Gastroenterology 2008 Apr; 134(4 Suppl. 1): A551. Plus poster presented at Digestive Disease Week; 2008 May 17-22; San Diego (CA)
53. Movetis. Thorough corrected QT interval (QTc) study to evaluate possible effects of prucalopride on ECG parameters [Clini-calTrials.gov identifier NCT00903747]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Oct 27]
54. Movetis NV. Movetis obtains EU authorisation for the commercialisation of Resolor® (prucalopride). First launch of Resolor anticipated in Q1 2010 [online]. Available from URL: http://www.movetis.com/news-events/press/releases/ eu-authorisation-commercialisation-resolor?linkid = homeblock [Accessed 2009 Oct 27]